Skin properties improving agent for oral administration

Patent metadata

Field	Value
Publication number	US-9439933-B2
Application number	US-201113805908-A
Country	US
Kind code	B2
Filing date	Jun 27, 2011
Priority date	Jun 28, 2010
Publication date	Sep 13, 2016
Grant date	Sep 13, 2016

Abstract

Disclosed is a skin property-improving agent which exerts excellent effects by oral administration. The skin property-improving agent for oral administration contains, as an active ingredient, a bacterium belonging to the genus Streptococcus and a bacterium belonging to the genus Bifidobacterium , or fermented milk containing the two bacteria.

First claim

The invention claimed is:

1. A method for treating skin damage arising from ultraviolet radiation in a subject in need thereof, the method consisting of orally ingesting a composition consisting of, as an active ingredient, (i) a bacterium of genus Streptococcus and a bacterium of genus Bifidobacterium , (ii) fermented milk consisting of the two bacteria;
wherein each of the bacteria are present in the composition in an amount of about 10 3 to 10 13 CFU, and are (A) the bacterium of-genus Streptococcus is Streptococcus thermophilus YIT 2021 (FERM BP-7537); and the bacterium of genus Bifidobacterium is Bifidobacterium breve YIT 12272 (FERM BP-11320);
(B) the bacterium of genus Streptococcus is Streptococcus thermophilus YIT 2084 (FERM BP-10879); and the bacterium of genus Bifidobacterium is Bifidobacterium breve YIT 12272 (FERM BP-11320);
(C) the bacterium of genus Streptococcus is Streptococcus thermophilus YIT 2084 (FERM BP-10879); and the bacterium of genus Bifidobacterium is Bifidobacterium breve YIT 4065 (FERM BP-8223); or
(D) the bacterium of genus Streptococcus is Streptococcus thermophilus YIT 2021 (FERM BP-7537); and the bacterium of genus Bifidobacterium is Bifidobacterium breve YIT 4065 (FERM BP-6223).

2. The method of claim 1 , further comprising orally ingesting galacto-oligosaccharide.

3. The method of claim 1 , wherein the composition inhibits a reduction in water content of stratum corneum caused by ultraviolet irradiation.

4. The method of claim 1 , wherein the composition promotes an increase in water content of stratum corneum.

5. The method of claim 1 , wherein the bacterium of genus Streptococcus is Streptococcus thermophilus YIT 2021 (FERM BP-7537) and the bacterium of genus Bifidobacterium is Bifidobacterium breve YIT 12272 (FERM BP-1 1320).

6. The method of claim 1 , wherein the bacterium of genus Streptococcus is Streptococcus thermophilus YIT 2084 (FERM BP-10879); and the bacterium of genus Bifidobacterium is Bifidobacterium breve YIT 12272 (FERM BP-11320).

7. The method of claim 1 , wherein the bacterium of genus Streptococcus is Streptococcus thermophilus YIT 2084 (FERM BP-10879); and the bacterium of genus Bifidobacterium is Bifidobacterium breve YIT 4065 (FERM BP-6223).

8. The method of claim 1 , wherein the bacterium of genus Streptococcus is Streptococcus thermophilus YIT 2021 (FERM BP-7537) and the bacterium of genus Bifidobacterium is Bifidobacterium breve YIT 4065 (FERM BP-6223).

9. The method of claim 1 , wherein each of the bacteria are present in the composition in an amount of about 10 6 to 10 13 CPU.

10. The method of claim 1 , wherein each of the bacteria are present in the composition in an amount of about 10 7 to 10 13 CFU.

11. The method of claim 1 , wherein each of the bacteria are present in the composition in an amount of about 10 8 to 10 13 CPU.

12. The method of claim 1 , wherein each of the bacteria are present in the composition in an amount of about 10 3 to 10 8 CFU.

13. A method for treating skin damage arising from ultraviolet radiation selected from the group consisting of inflammation, immune suppression, or DNA damage in a subject in need thereof, the method consisting of orally ingesting a composition consisting of, as an active ingredient, (i) a bacterium of genus Streptococcus and a bacterium of genus Bifidobacterium , or (ii) fermented milk comprising the two bacteria;
wherein each of the bacteria are present in the composition in an amount of about 10 3 to 10 13 CFU, and are (A) the bacterium of-genus Streptococcus is Streptococcus thermophilus YIT 2021 (FERM BP-7537); and the bacterium of genus Bifidobacterium is Bifidobacterium breve YIT 12272 (FERM BP-11320);
(B) the bacterium of genus Streptococcus is Streptococcus thermophilus YIT 2084 (FERM BP-10879); and the bacterium of genus Bifidobacterium is Bifidobacterium breve YIT 12272 (FERM BP-11320);
(C) the bacterium of genus Streptococcus is Streptococcus thermophilus YIT 2034 (FERM BP-10879); and the bacterium of genus Bifidobacterium is Bifidobacterium breve YIT 4065 (FERM BP-6223); or
(D) the bacterium of genus Streptococcus is Streptococcus thermophilus YIT 2021 (FERM BP-7537); and the bacterium of genus Bifidobacterium is Bifidobacterium breve YIT 4065 (FERM BP-6223).

Assignees

• Masuoka Norie
• Kano Mitsuyoshi
• Miyazaki Kouji
• Sone Toshiro
• Yakult Honsha Kk

Inventors

• Masuoka Norie
• Kano Mitsuyoshi
• Miyazaki Kouji
• Sone Toshiro

Classifications

• A61P17/00

  Drugs for dermatological disorders · CPC title

• A61P17/16

  Emollients or protectives, e.g. against radiation · CPC title

• A61K35/20

  Milk; Whey; Colostrum · CPC title

• A23L33/135

  Bacteria or derivatives thereof, e.g. probiotics · CPC title

• A23V2200/3204

  Probiotics, living bacteria to be ingested for action in the digestive tract · CPC title